摘要
目的:探讨不孕症合并卵巢肿瘤手术史患者的IVF/ICSI-ET治疗的妊娠结局及安全性。方法:回顾性分析23例卵巢肿瘤保守性手术后行IVF/ICSI-ET治疗患者的临床结局及随访资料。结果:23例患者共35个新鲜移植周期,8个冷冻胚胎移植周期;平均基础FSH和E2分别为6.26±1.87 IU/L,41.9±24.7 pg/ml;平均Gn启动剂量165±59 IU,平均Gn使用总量1 516±866 IU,平均Gn使用天数8±3 d;hCG注射日E2峰值平均水平1 202±976 pg/ml;平均获卵数6.0±5.3个,平均成熟卵子数5.2±4.8个,受精率83.5%,平均可移植胚胎数3.1±2.7个,平均优质胚胎数2.8±2.8个,平均胚胎移植数1.8±0.7个;新鲜周期着床率29.0%,临床妊娠率28.6%;冻融胚胎周期着床率25.0%,临床妊娠率25.0%;平均随访时间(即首次IVF启动时间至末次随访日)为23个月,经IVF治疗后仅有1例复发,没有与卵巢肿瘤相关的死亡。结论:卵巢良性及交界性肿瘤经保守性手术治疗后合并不孕的患者,IVF-ET治疗有效且安全。
Objective： To evaluate fertility outcome and safety after the IVF treatment in patients who were treated conservatively for ovarian tumor. Methods： The clinical and follow-up outcomes of 23 infertile women who had been treated by IVF-ET after conservative surgery for ovarian tumor were retrospectively analyzed. Results： There were 35 fresh ET cycles and 8 frozen ET cycles for 23 patients. The mean basal FSH and E2 levels were 6.26 ± 1.87 IU/L and 41.9 ± 24.7 pg/ml, respectively. The mean peak E2 level on the day of hCG administration was 1 202 _ 976 pg/ml. The mean number of oocytes and mature oocytes retrieved was 6.0 ±5.3 and 5.2 ± 4.8, respectively, with the mean fertilization rate of 83.5%. The mean number of portable embryos, superior embryos and transferred embryos was 3.1 ± 2.7, 2.8 ± 2.8 and 1.8± 0.7, respectively. Ten pregnancies were achieved in the 35 fresh embryo cycles with the clinical pregnancy rate of 28.6% and implantation rate of 29%, whereas two pregnancies were achieved in the 8 frozen embryo cycles with the clinical pregnancy rate of 25% and implantation rate of 25%. The mean follow-up time that elapsed since the first IVF cycle was 23 months. There was only one case of recurrence diagnosed in our patients after IVF treatment, and no disease-related deaths occurred in our series and all patients were without evidence of disease at the time of last follow-up. Conclusion： IVF-ET treatment could be used effectively and safely in infertile patients with the history of conservative operation for benign and borderline ovarian tumor.
出处
《生殖与避孕》
CAS
CSCD
2013年第2期128-132,共5页
Reproduction and Contraception
基金
国家自然青年科学基金资助项目
项目号:81100470
